Rapid Response to Vedolizumab Therapy in Biologic-Naïve Patients With Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology - United Kingdom
doi 10.1016/j.cgh.2018.05.026
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients With Inflammatory Bowel Diseases

Journal of Clinical Medicine
2020English

Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease

Inflammatory Bowel Diseases
AllergyImmunologyGastroenterology
2019English

Review Article: Predictors of Response to Vedolizumab and Ustekinumab in Inflammatory Bowel Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Inflammatory Bowel Diseases Activity in Patients Undergoing Pelvic Radiation Therapy

Journal of Gastrointestinal Oncology
OncologyGastroenterology
2017English

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Steatohepatitis in Patients With Inflammatory Bowel Diseases in Karelia

Journal of Biomedical Technologies
2014English

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases

Frontiers in Immunology
AllergyImmunology
2018English

Physiological Intermolecular Modification Spectroscopy for the Prediction of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Diseases

Digestive Diseases
MedicineGastroenterology
2014English

Exercise in Patients With Inflammatory Bowel Diseases: Current Perspectives

Clinical and Experimental Gastroenterology
Gastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy